| Width: | 175px |
| Cas Number: | 1875-50-9 |
| Pubchem: | 122316 |
| Chemspiderid: | 13409715 |
| Unii: | UZ2TR4YN26 |
| Synonyms: | AGN-1135; Racemic rasagiline; (±)-Rasagiline; (RS)-Rasagiline; N-Propargyl-1-aminoindane |
| Iupac Name: | N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine |
| C: | 12 |
| H: | 13 |
| N: | 1 |
| Smiles: | C#CCNC1CCC2=CC=CC=C12 |
| Stdinchi: | 1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2 |
| Stdinchikey: | RUOKEQAAGRXIBM-UHFFFAOYSA-N |
AGN-1135 (also known as racemic rasagiline or as N-propargyl-1-aminoindane) is a monoamine oxidase inhibitor (MAOI) that was never marketed.[1] [2] It is the racemic form of rasagiline and is a mixture of the R(+)-enantiomer (rasagiline; TVP-1012) and S(–)-enantiomer (TVP-1022). Like rasagiline, AGN-1135 is a selective monoamine oxidase B (MAO-B) inhibitor. Virtually all of the MAOI activity of AGN-1135 lies in rasagiline, which is several orders of magnitude more potent as an MAO-B inhibitor than the S(–)-enantiomer. In relation to this, enantiopure rasagiline was developed and marketed for use as a pharmaceutical drug rather than AGP-1135.